Understanding the atomistic resolution changes during the self-assembly of amyloid
peptides or proteins is important to develop compounds or conditions to alter the …

Aggregation of amyloid-β (Aβ) peptides is characteristic of Alzheimer's disease (AD), which
is the most common neurodegenerative disorder. Increasing evidence shows that Aβ …

Monosialoganglioside GM1-bound amyloid β-peptides have been found in patients' brains
exhibiting early pathological changes of Alzheimer's disease. Herein, we report the ability of …

The interactions of amyloid oligomers with membranes are known to contribute to cellular
toxicity. Numerous in vitro experimental studies reported on the insertion of oligomers of …

Alzheimer's disease remains largely unknown, and currently there is no complete cure for
the disease. New synthetic approaches have been developed to create multi-target agents …

Alzheimer's disease is a progressive degenerative condition that mainly affects cognition
and memory. Recently, distinct clinical and neuropathological phenotypes have been …

The interactions of amyloid proteins with membranes have been subject to many
experimental and computational studies, as these interactions contribute in part to …

Histidine tautomeric behaviors have been considered origin factors for controlling the
structure and aggregation properties of misfolding peptides. Except for tautomeric behaviors …

Protein misfolding diseases (PMDs) in humans are characterized by the deposition of
protein aggregates in tissues, including Alzheimer's disease, Parkinson's disease, type 2 …

Chronic traumatic encephalopathy (CTE) is a unique progressive neurodegenerative
tauopathy pathologically related to the aggregation of the tau protein to neurofibrillary …